Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression
Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression
复制标题
DOI：
10.1093/fampra/cmv100
复制
发表时间：
2016-02-01
期刊：
影响因子：
2.2
通讯作者：
Schneider, F. David
中科院分区：
文献类型：
--
作者：
Brieler, Jay A.;Lustman, Patrick J.;Schneider, F. David
目标。抑郁症在糖尿病中普遍存在，并与高血糖、发病率和死亡率的风险增加有关。由于缺乏相关数据，抗抑郁药物(ADM)对血糖控制的效果尚不确定。我们试图确定ADM的使用是否与2型糖尿病抑郁患者的血糖控制有关。研究设计和方法。使用2008年至2013年门诊初级保健就诊的电子病历登记数据进行了一项回溯性队列研究(n=1399)。抑郁症和2型糖尿病通过ICD-9-CM编码确定；ADM的使用根据处方顺序确定；血糖控制通过糖化血红蛋白(A1c)的测量确定。良好的血糖控制被定义为A1c
Objective. Depression is prevalent in diabetes and is associated with increased risks of hyperglycaemia, morbidity and mortality. The effect of antidepressant medication (ADM) on glycaemic control is uncertain owing to a paucity of relevant data. We sought to determine whether the use of ADM is associated with glycaemic control in depressed patients with type 2 diabetes.Research design and methods. A retrospective cohort study (n = 1399) was conducted using electronic medical record registry data of ambulatory primary care visits from 2008 to 2013. Depression and type 2 diabetes were identified from ICD-9-CM codes; ADM use was determined from prescription orders; and glycaemic control was determined from measures of glycated haemoglobin (A1c). Good glycaemic control was defined as A1c